Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015

Volume 4, Issue 3, Part 3.

Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Gregory Dore from the Kirby Institute, UNSW Australia about the C-EDGE CO-STAR study.

Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015

Volume 4, Issue 3, Part 2.

Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Graham Foster from Queen Mary University of London about the ASTRAL-3 study.

Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015

Volume 4, Issue 3, Part 1.

Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Vincent Leroy from Grenoble University Hospital about the ALLY-3+ study.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION

Special Edition 2014, Issue 2, Part 3.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION

Special Edition 2014, Issue 2, Part 2.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION

Special Edition 2014, Issue 2, Part 1.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY

Special Edition 2014, Issue 1, Part 2.

Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore discusses patients who have genotype 3 or cirrhosis, are interferon-ineligible/intolerant, or have failed previous therapy with program director, Dr. Raymond Chung.